UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Role of multimodality therapy in cIIIA-N2 non-small cell lung cancer: perspective

Japanese journal of clinical oncology, 2016-12, Vol.46 (12), p.1174-1178

Horinouchi, Hidehito

2016

Volltextzugriff (PDF)

A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2022-05, Vol.25 (3), p.619-628

2022

Volltextzugriff (PDF)

Pembrolizumab plus pemetrexed‐platinum for metastatic nonsquamous non–small‐cell lung cancer: KEYNOTE‐189 Japan Study

Cancer science, 2021-08, Vol.112 (8), p.3255-3265

2021

Volltextzugriff (PDF)

Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study

European journal of cancer (1990), 2019-05, Vol.113, p.78-86

2019

Volltextzugriff (PDF)

Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma

Lung cancer (Amsterdam, Netherlands), 2015-05, Vol.88 (2), p.154-159

2015

Volltextzugriff (PDF)

History of Japan Clinical Oncology Group (JCOG) Lung Cancer Study Group

Japanese journal of clinical oncology, 2020-05, Vol.50 (5), p.502-511

2020

Volltextzugriff (PDF)

Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions

Scientific reports, 2021-09, Vol.11 (1), p.18762-18762, Article 18762

2021

Volltextzugriff (PDF)

Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2018-10, Vol.124, p.179-188

2018

Volltextzugriff (PDF)

Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody

Cancer Immunology, Immunotherapy, 2020-01, Vol.69 (1), p.15-22

2020

Volltextzugriff (PDF)

Feasibility of next-generation sequencing (Oncomine™ DX Target Test) for the screening of oncogenic mutations in advanced non-small-cell lung cancer patients

Japanese journal of clinical oncology, 2021-07, Vol.51 (7), p.1114-1122

2021

Volltextzugriff (PDF)

Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab

Cancer Immunology, Immunotherapy, 2022-02, Vol.71 (2), p.387-398

2022

Volltextzugriff (PDF)

Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC

Journal of thoracic oncology, 2021-12, Vol.16 (12), p.2078-2090

2021

Volltextzugriff (PDF)

Medical management of older patients with lung cancer

Japanese journal of clinical oncology, 2022-10, Vol.52 (10), p.1082-1088

2022

Volltextzugriff (PDF)

Phase II study of ceritinib in alectinib‐pretreated patients with anaplastic lymphoma kinase‐rearranged metastatic non‐small‐cell lung cancer in Japan: ASCEND‐9

Cancer science, 2018-09, Vol.109 (9), p.2863-2872

2018

Volltextzugriff (PDF)

Another Pirate in the Red Ocean? CD73-Targeted Therapy in EGFR-Mutated NSCLC

Journal of thoracic oncology, 2023-05, Vol.18 (5), p.552-555

Horinouchi, Hidehito

2023

Volltextzugriff (PDF)

Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapy

Lung cancer (Amsterdam, Netherlands), 2016-09, Vol.99, p.4-10

2016

Volltextzugriff (PDF)

Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression

Journal of cancer research and clinical oncology, 2021, Vol.147 (1), p.245-251

2021

Volltextzugriff (PDF)

Study protocol for JCOG1807C (DEEP OCEAN): a interventional prospective trial to evaluate the efficacy and safety of durvalumab before and after operation or durvalumab as maintenance therapy after chemoradiotherapy against superior sulcus non-small cell lung cancer

Japanese journal of clinical oncology, 2022-04, Vol.52 (4), p.383-387

2022

Volltextzugriff (PDF)

Whole genome sequencing to identify predictive markers for the risk of drug-induced interstitial lung disease

PloS one, 2019-10, Vol.14 (10), p.e0223371

2019

Volltextzugriff (PDF)

An ATR-PrimPol pathway confers tolerance to oncogenic KRAS-induced and heterochromatin-associated replication stress

Nature communications, 2023-08, Vol.14 (1), p.4991-4991, Article 4991

2023

Volltextzugriff (PDF)

Advances in cancer DNA methylation analysis with methPLIER: use of non-negative matrix factorization and knowledge-based constraints to enhance biological interpretability

Experimental and Molecular Medicine, 2024, 56(0), , pp.646-655

2024

Volltextzugriff (PDF)

Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression

Cancer Immunology, Immunotherapy, 2022-03, Vol.71 (3), p.737-746

2022

Volltextzugriff (PDF)

SY4-4 Immune checkpoint inhibitors in perioperative treatment in lung cancer

Annals of oncology, 2021-07, Vol.32, p.S249-S249

Horinouchi, Hidehito

2021

Volltextzugriff (PDF)

Early change in the clearance of pembrolizumab reflects the survival and therapeutic response: A population pharmacokinetic analysis in real-world non-small cell lung cancer patients

Lung cancer (Amsterdam, Netherlands), 2022-11, Vol.173, p.35-42

2022

Volltextzugriff (PDF)

Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor

Clinical lung cancer, 2022-07, Vol.23 (5), p.386-392

2022

Volltextzugriff (PDF)

1 – 25 von 307

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(263)
Mit Volltextzugriff
(290)

Publikationsform

Artikel
(305)
Berichte
(2)

Sprache

Englisch
(283)
Japanisch
(66)

Erscheinungsjahr

n.n

Thema

Science & Technology
(163)
Life Sciences & Biomedicine
(159)
Oncology
(143)
Humans
(115)
Female
(80)
Male
(77)
Lung Cancer
(76)
Aged
(74)
Lung Neoplasms - Drug Therapy
(73)
Middle Aged
(72)
Adult
(67)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(58)
Chemotherapy
(58)
Patients
(51)
Respiratory System
(51)
Lung Neoplasms - Pathology
(49)
Original
(43)
Retrospective Studies
(41)
Cancer Therapies
(36)
Non-Small Cell Lung Cancer
(35)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Role of multimodality therapy in cIIIA-N2 non-small cell lung cancer: perspective

A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer

Pembrolizumab plus pemetrexed‐platinum for metastatic nonsquamous non–small‐cell lung cancer: KEYNOTE‐189 Japan Study

Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study

Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma

History of Japan Clinical Oncology Group (JCOG) Lung Cancer Study Group

Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions

Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer

Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody

Feasibility of next-generation sequencing (Oncomine™ DX Target Test) for the screening of oncogenic mutations in advanced non-small-cell lung cancer patients

Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab

Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC

Medical management of older patients with lung cancer

Phase II study of ceritinib in alectinib‐pretreated patients with anaplastic lymphoma kinase‐rearranged metastatic non‐small‐cell lung cancer in Japan: ASCEND‐9

Another Pirate in the Red Ocean? CD73-Targeted Therapy in EGFR-Mutated NSCLC

Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapy

Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression

Study protocol for JCOG1807C (DEEP OCEAN): a interventional prospective trial to evaluate the efficacy and safety of durvalumab before and after operation or durvalumab as maintenance therapy after chemoradiotherapy against superior sulcus non-small cell lung cancer

Whole genome sequencing to identify predictive markers for the risk of drug-induced interstitial lung disease

An ATR-PrimPol pathway confers tolerance to oncogenic KRAS-induced and heterochromatin-associated replication stress

Advances in cancer DNA methylation analysis with methPLIER: use of non-negative matrix factorization and knowledge-based constraints to enhance biological interpretability

Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression

SY4-4 Immune checkpoint inhibitors in perioperative treatment in lung cancer

Early change in the clearance of pembrolizumab reflects the survival and therapeutic response: A population pharmacokinetic analysis in real-world non-small cell lung cancer patients

Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor

Suchergebnisse filtern